Physician

Archana Nayani, M.D.

According to 2025 Medicare claims, Archana Nayani, M.D. (NPI: 1548524770) practices medical oncology in the Springfield, IL market, with the plurality of this provider's patient population coming from Sangamon, IL. This provider's primary affiliated billing organization is SPRINGFIELD CLINIC, LLP (NPI: 1780638478; TIN: 370701328) and primary practice location at 62703-2403. Nayani is affiliated with the Springfield Clinic ACO, LLC (ACO ID: A2587), IRCCO (ACO ID: A2619), and HSHS ACO, L.L.C. (ACO ID: A2783), participating under the MSSP model.

Nayani's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 287 traditional Medicare patients, billed 62,135 HCPCS/CPT codes, and received $827,542 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,707 prescription claims across 252 beneficiaries totaling $3,121,889 in drug costs, led by Verzenio (Abemaciclib). DME data shows 86 claims. Open Payments data shows 35 records totaling $829. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $8,292 to $827,542. Similarly, Part D prescription costs have risen steadily, from $2,398 to $3,121,889. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	41	99	$8,292
2019	200	598	$45,494
2020	211	778	$65,226
2021	299	886	$83,786
2022	191	578	$54,958
2023	260	32,712	$480,873
2024	287	62,135	$827,542

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	19	42	$2,398
2016	46	97	$35,467
2017	44	122	$181,834
2018	34	71	$96,507
2019	54	223	$10,291
2020	74	603	$452,082
2021	151	1,149	$1,156,014
2022	152	1,256	$2,125,465
2023	204	1,307	$2,245,923
2024	252	1,707	$3,121,889

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	29	$1,309
2023	N/R	114	$9,390
2024	N/R	86	$2,335

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	169	458	$96
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	45	119	$45
36415	Insertion of needle into vein for collection of blood sample	130	233	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	128	320	$8
J7050	Infusion, normal saline solution, 250 cc	46	214	$1

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Verzenio	Abemaciclib	24	672	$380,309
Calquence	Acalabrutinib Maleate	22	660	$312,215
Nubeqa	Darolutamide	17	510	$233,395
Lenalidomide	Lenalidomide	12	336	$231,934
Ibrance	Palbociclib	13	364	$206,334

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	18	$837
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	18	$514
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	20	$358
J8520	Capecitabine, oral, 150 mg	N	N/R	17	$327
J8521	Capecitabine, oral, 500 mg	N	N/R	13	$299

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	35	$829	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Archana Nayani, M.D.?

Tedicare shows public-source Medicare data for Archana Nayani, M.D. (NPI 1548524770), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Archana Nayani, M.D. have ACO affiliation data?

Archana Nayani, M.D. is shown with ACO affiliation data for Springfield Clinic ACO, LLC (MSSP, ACO ID A2587), IRCCO (MSSP, ACO ID A2619), and HSHS ACO, L.L.C. (MSSP, ACO ID A2783).

What billing organization is linked to Archana Nayani, M.D.?

Archana Nayani, M.D. is linked to SPRINGFIELD CLINIC, LLP (billing NPI 1780638478) in the available physician profile data.

Does Archana Nayani, M.D. have Open Payments data?

Archana Nayani, M.D. has 35 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.